{"id":112943,"date":"2022-07-15T12:23:09","date_gmt":"2022-07-15T12:23:09","guid":{"rendered":"https:\/\/euretina.org\/?post_type=resource&p=112943"},"modified":"2022-08-15T16:51:21","modified_gmt":"2022-08-15T16:51:21","slug":"speakers-corner-session-mixed-session-8","status":"publish","type":"resource","link":"https:\/\/euretina.org\/resource\/speakers-corner-session-mixed-session-8\/","title":{"rendered":"Speakers’ Corner 8: Mixed Session"},"content":{"rendered":"\n
Time & Date:<\/strong> 2 September, 16:15 – 17:15 CEST Speakers:<\/strong><\/p>\n\t\t\t<\/div>\n\t\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t Presentations:<\/strong><\/p>\n\t\t\t<\/div>\n\t\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t Speakers & Presentations:<\/strong><\/p>\n\t\t\t<\/div>\n\t\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n J. Garweg SWITZERLAND<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t 16:15<\/em> Welcome<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n E. Aydin TURKEY<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t 16:17 <\/em>The Investigation of Relationship between Diabetes, Diabetic Neuropathy, and Retinal Neurodegeneration<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n T-E. Tan SINGAPORE<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t 16:22 <\/em>Retinal Neural Dysfunction in Diabetes Revealed with Handheld Chromatic Pupillometry<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n P. Schlottmann ARGENTINA<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t 16:27<\/em> Efficacy, Durability and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results From the Phase 3 YOSEMITE and RHINE Trials<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n M. Barakat USA<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t 16:32<\/em> Brolucizumab for the Treatment of Diabetic Macular Edema: 52-week Results from the KINGFISHER Study<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n J. Garweg SWITZERLAND<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t 16:37<\/em> Brolucizumab for treatment of diabetic macular edema (DME): 100-week results from the KESTREL and KITE studies<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n R. Khoramnia GERMANY<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t 16:42<\/em> Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n J. Garweg SWITZERLAND<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t 16:47<\/em> Effect of Finerenone on Occurrence of Vision-threatening Events in Patients with DR<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n A.M. Mart\u00ednez SPAIN<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t 16:52<\/em> Anatomical biomarkers after dexamethasone intravitreal implant in diabetic macular edema patients according to new ESASO Classification<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n
Moderator:<\/strong> J. Garweg SWITZERLAND<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n